Jerkeman A, Astermark J, Hedner U, Lethagen S, Olsson C G, Berntorp E
Department for Coagulation Disorders, University Hospital, Malmö, Sweden.
Thromb Res. 2000 Jun 15;98(6):467-71. doi: 10.1016/s0049-3848(00)00203-6.
In order to study the effect of different intensities of anti-vitamin K treatment on coagulation parameters, 23 patients with venous thromboembolism were given, after the initial treatment period, warfarin at doses giving an International Normalised Ratio of 1.3-2.0 for 4 weeks, and of 1.1-1.3 for another 4 weeks. Blood samples were taken at the end of each of these periods and 4 weeks after the end of warfarin treatment. The vitamin K-dependent coagulation factors VII, IX, and X, as well as the inhibitor protein C and its cofactor protein S, all showed a highly significant correlation with treatment intensity. This was to some extent also true for the coagulation activation markers, prothrombin fragment 1+2 and thrombin-antithrombin complex. Ratios of pro- and anticoagulant factors in some instances showed a decrease at therapeutical (International Normalised Ratio) levels, and also sometimes with reduced warfarin treatment intensity. Taken together, our results encourage further research addressing issues of varying treatment intensity with warfarin and alternative methods for monitoring of anti-vitamin K treatment.
为研究不同强度的抗维生素K治疗对凝血参数的影响,23例静脉血栓栓塞患者在初始治疗期后,接受了华法林治疗,剂量为使国际标准化比值达到1.3 - 2.0,持续4周,之后剂量调整为1.1 - 1.3,再持续4周。在每个阶段结束时以及华法林治疗结束后4周采集血样。维生素K依赖的凝血因子VII、IX和X,以及抑制蛋白C及其辅因子蛋白S,均与治疗强度呈现高度显著相关性。对于凝血激活标志物凝血酶原片段1 + 2和凝血酶 - 抗凝血酶复合物,在某种程度上也是如此。促凝和抗凝因子的比率在治疗性(国际标准化比值)水平时,有时会降低,在华法林治疗强度降低时也会如此。总体而言,我们的结果鼓励进一步研究华法林不同治疗强度的相关问题以及监测抗维生素K治疗的替代方法。